Frontlight ResearchEarly access
Taking peoplePhase 2/3
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Key facts
- Who runs it
- Shanghai Jiaolian Drug Research and Development Co., Ltd
- Where
- China21 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 216 people, planned
- Started
- 30 Jul 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- B007
- Cyclosporin Capsules
- Record updated
- 5 May 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy
- Subjects with glomerular filtration rate(eGFR) ≥ 45 mL/min/1.73 m2
- If taking Angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists/sodium-glucose cotransporter 2 inhibitors/endothelin inhibitors, a stable dose within 4 weeks before randomization
- Subjects with 24-hour elevated urinary protein in accordance with the prescribed conditions
- Subjects whose laboratory test results meet the prescribed standards during the screening period
- Subjects who have fully understood this study and voluntarily signed the informed consent form;
- Subjects who are able to follow the study protocol as judged by the investigator
Who cannot take part
- Subjects with secondary membranous nephropathy or primary membranous nephropathy whose pathological reports suggest concomitant crescent bodies
- Subjects identified by the investigator as previously resistant to CD20 monoclonal antibody or cyclosporine
- Subjects who have received medication prescribed for membranous nephropathy
- Subjects with concomitant prescribed diseases
- Subjects who received live vaccination, major surgery, or participated in other clinical trials within 28 days before receiving the study drug
- Subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment
- Pregnant or lactating women; women of childbearing potential who have not been sterilized do not agree to use appropriate contraceptive measures during treatment and for at least 12 months after the last dose of the study drug
- For male subjects who have not been sterilized: those who do not consent to the use of barrier contraception during the study period and for at least 12 months after the last administration of the study drug, and who do not consent to the use of other contraceptive methods by their spouses
- Subjects with a known history of severe allergic reactions to humanized monoclonal antibodies, or known allergies to any component of cyclosporine or B007
- Subjects with positive hepatitis B surface antigen; those with positive hepatitis C virus antibody; those with a history of immunodeficiency or suffer from other acquired or congenital immunodeficiency diseases
- Other conditions unsuitable for participation in this study determined by the Investigator
- Subjects with CD4+ T lymphocyte count < 400 cells/μL
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
The 2 groups in the trial
- B007Treatment being tested
- Cyclosporin CapsulesExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy.
- Fit questions
- Built from NCT06470191, who can take part
- Record updated
- 5 May 2026